<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        14-174-20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Imipenem/Cilastatin Kabi 500MG/500MG VIAL
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CILASTATIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        500
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        313.35
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="ACS Dobfar S.P.A" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            ACS Dobfar S.P.A
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 606]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ALHAYA MEDICAL CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Fresenius Kabi Deutschland GmbH 
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01DH51 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Imcilta belongs to a group of medicines called carbapenem antibiotics. It kills a wide range of bacteria (germs) that cause infections in various parts of the body in adults and children one year of age and above.</p><p><strong>Treatment</strong></p><p>Your doctor has prescribed Imcilta because you have one (or more) of the following types of infection:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Complicated infections in the abdomen</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infection affecting the lungs (pneumonia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infections that you can catch during or after the delivery of your baby</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Complicated urinary tract infections</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Complicated skin and soft tissue infections</p><p>Imcilta may be used in the management of patients with low white blood cell counts, who have fever that is suspected to be due to a bacterial infection.</p><p>Imcilta may be used to treat bacterial infection of the blood which might be associated with a type of infection mentioned above.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Imcilta</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to imipenem, cilastatin or any of the other ingredients of this medicine (listed in section 6)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to other antibiotics such as penicillins, cephalosporins, or carbapenems</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or nurse before using Imcilta</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have allergies to any medicines including antibiotics (sudden life-threatening allergic reactions require immediate medical treatment)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have colitis or any other gastrointestinal disease</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have kidney or urinary problems, including reduced kidney function (Imcilta blood levels increase in patients with reduced kidney function. Central nervous system adverse reactions may occur if the dose is not adjusted to the kidney function)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have any central nervous system disorders such as localized tremors or epileptic seizures (fits)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have liver problems</p><p>You may develop a positive test (Coombs test) which indicates the presence of antibodies that may destroy red blood cells. Your doctor will discuss this with you.</p><p><em>Children</em></p><p>Imcilta is not recommended in children less than one year of age or children with</p><p>kidney problems.</p><p><strong>Other medicines and Imcilta</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>Tell your doctor if you are taking ganciclovir which is used to treat some viral infections.</p><p>Also, tell your doctor if you are taking valproic acid or sodium valproate (used to treat epilepsy, bipolar disorder, migraine, or schizophrenia) or any blood thinners such as warfarin.</p><p>Your doctor will decide whether you should use Imcilta in combination with these medicines.</p><p><strong>Pregnancy and breast-feeding</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have</p><p>a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>&nbsp;</p><p>Page 2 of 8</p><p>&nbsp;</p><p>It is important that you tell your doctor if you are pregnant or are planning to become pregnant before receiving Imcilta. Imipenem/cilastatin has not been studied in pregnant women. Imcilta should not be used during pregnancy unless your doctor decides the potential benefit justifies the potential risk to the developing baby.</p><p>It is important that you tell your doctor if you are breast-feeding or if you intend to breast-feed before receiving Imcilta. Small amounts of this medicine may pass into breast milk and it may affect the baby. Therefore, your doctor will decide whether you should use Imcilta while breast-feeding.</p><p><strong>Driving and using machines</strong></p><p>There are some side effects associated with this product (such as seeing, hearing, or feeling something that is not there, dizziness, sleepiness, and a spinning sensation) that may affect some patients&#39; ability to drive or operate machinery (see section 4).</p><p><strong>Imcilta contains sodium</strong></p><p>Imcilta 250 mg/250 mg contains 0.8 mmol (18.8 mg) sodium per dose and Imcilta</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>500 mg/500 mg contains 1.6 mmol (37.5 mg) sodium per dose. To</p></td><td><p>be taken into</p></td></tr><tr><td><p>consideration by patients on a controlled sodium diet.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Imcilta will be prepared and given to you by a doctor or another health-care professional. Your doctor will decide how much Imipenem/Cilastatin you need.</p><p><u>Use in adults and adolescents</u></p><p>The recommended dose for adults and adolescents is 500 mg/500 mg every 6 hours or 1,000 mg/1,000 mg every 6 or 8 hours. If you have kidney problems your doctor may lower your dose.</p><p><u>Use in children</u></p><p>The recommended dose for children one year of age or older is 15/15 or 25/25 mg/kg/dose every 6 hours. Imcilta is not recommended in children under one year of age and children with kidney problems.</p><p><u>Method of administration</u></p><p>Imcilta is given intravenously (into a vein) over 20-30 minutes for a dose of &le;500 mg/500 mg or 40-60 minutes for a does of &gt;500 mg/500 mg. The rate of infusion may be slowed if you feel sick.</p><p><strong>If you use more Imcilta than you should</strong></p><p>Page 3 of 8</p><p>&nbsp;</p><p>Symptoms of overdose may include seizures, confusion, tremors, nausea, vomiting, low blood pressure and slow heart rate. If you are concerned that you may have been given too much Imcilta, contact your doctor or another healthcare professional immediately.</p><p><strong>If you forget to use Imcilta</strong></p><p>If you are concerned that you may have missed a dose, contact your doctor or another healthcare professional immediately.</p><p>Do not take a double dose to make up for a forgotten dose.</p><p><strong>If you stop using Imcilta</strong></p><p>Do not stop using Imcilta until your doctor tells you to.</p><p>If you have any further questions on the use of this medicine, ask your doctor or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>The following side-effects occur rarely, however if they do occur, while receiving or after receiving Imcilta, the medicine must be stopped and your doctor contacted immediately.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic reactions including rash, swelling of the face, lips, tongue and/or throat (with difficulty in breathing or swallowing), and/or low blood pressure.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin peeling (toxic epidermal necrolysis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe skin reactions (Stevens-Johnson syndrome and erythema multiforme)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe skin rash with loss of skin and hair (exfoliative dermatitis)</p><p>Other possible side effects:</p><p><strong>Common (</strong>may affect up to 1 in 10 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nausea, vomiting, diarrhoea. Nausea and vomiting appear to occur more frequently in patients with low number of white blood cells</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling and redness along a vein which is extremely tender when touched</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal liver function detected by blood tests</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increase in some white blood cells</p><p><strong>Uncommon (</strong>may affect up to 1 in 100 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Local skin redness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Local pain and formation of a firm lump at the injection site</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin itchiness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hives</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fever</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood disorders affecting the cell components of the blood and usually detected by blood tests (symptoms may be tiredness, paleness of skin, and prolonged bruising after injury)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal kidney, liver and blood function detected by blood tests</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tremors and uncontrolled twitching of muscles</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Seizures (fits)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Psychic disturbances (such as mood swings and impaired judgment)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Seeing, hearing or feeling something that is not there (hallucinations)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Confusion</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness, sleepiness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low blood pressure</p><p><strong>Rare (</strong>may affect up to 1 in 1,000 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fungal infection (candidiasis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Staining of the teeth and/or tongue</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the colon with severe diarrhoea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Disturbances in taste</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inability of the liver to perform normal function</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the liver</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inability of the kidney to perform normal function</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in the amount of urine, changes in urine colour</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Disease of the brain, tingling sensation (pins and needles), localised tremor</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hearing loss</p><p><strong>Very rare (</strong>may affect up to 1 in 10,000 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe loss of liver function due to inflammation (fulminant hepatitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of stomach or intestine (gastro-enteritis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of intestine with bloody diarrhoea (haemorrhagic colitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Red swollen tongue, overgrowth of the normal projections on the tongue giving it a hairy appearance, heartburn, sore throat, increase in the production of saliva</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stomach pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A spinning sensation (vertigo), headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ringing in the ears (tinnitus)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pain in several joints, weakness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Irregular heartbeat, the heart beating forcefully or rapidly</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chest discomfort, difficulty breathing, abnormally fast and superficial breathing, pain in the upper spine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Flushing, bluish discoloration of the face and lips, skin texture changes, excessive sweating</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Itching of the vulva in women</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in the amounts of blood cells</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Worsening of a rare disease associated with muscle weakness (aggravation of myasthenia gravis)</p><p><strong>Not known </strong>(frequency cannot be estimated from the available data)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal movements</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Agitation</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor or nurse. This includes any possible side effects</p><p>not listed in this leaflet.</p><p>To report any side effect(s):</p><p>&middot; Saudi Arabia:</p><table cellspacing="0" cellpadding="0" align="left"><tbody><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC):</p><p>- SFDA Call Center: 19999</p><p>&nbsp; - E-mail: npc.drug@sfda.gov.sa</p><p>&nbsp; - Website: https://ade.sfda.gov.sa/</p><p>&middot; Other GCC States:</p><p>- Please contact the relevant competent authority.</p><p>By reporting side effects, you can help provide more information on the safety of this medicine.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the outer carton and the vials after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>Before opening:</p><p>Do not store above 25&ordm;C.</p><p>After first opening/reconstitution:</p><p>Reconstituted/diluted solutions should be used immediately. The time interval between the</p><p>beginning of reconstitution and the end of intravenous infusion should not exceed two hours.</p><p>Do not freeze the reconstituted solution.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 500 mg imipenem (as 530mg imipenem monohydrate) and 500 mg cilastatin (as 530mg cilastatin sodium salt)</p><p>The other ingredient is sodium hydrogen carbonate</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Imcilta 500 mg imipenem and 500 mg cilastatin is a white to almost white or yellow powder delivered in 20 ml glass vials and 100 ml glass bottles.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorization Holder:<br />Fresenius Kabi Deutschland GmbH</p><p>Manufacturer:</p><p>ACS Dobfar S.P.A, Nucleo Industriale S. atto, S. Nicolo a Tordino, Teramo, Italy</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                05/2016
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ينتمي إمسيلتا إلى مجموعه من الأدوية المضادات الحيوية التي تسمي الكاربابينيميات. وهو يقتل مجموعه واسعه من البكتيريا (الجراثيم) التي تسبب العدوى في أجزاء مختلفة من الجسم في البالغين والأطفال من عمر سنه واحده فأكثر.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>العلاج</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">لقد وصف الطبيب الخاص بك إمسيلتا لأن لديك واحد (أو أكثر) من أنواع العدوى التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإنتانات المعقدة في البطن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوى التي تصيب الرئتين (التهاب الرئوي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإصابات التي يمكنك التقاطها اثناء أو بعد الولادة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهابات المسالك البولية المعقدة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهابات الجلد والأنسجة الناعمة المعقدة</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن استخدام إمسيلتا في علاج المرضي الذين يعانون من انخفاض عدد خلايا الدم البيضاء ولديهم حمي يشتبه في انها ناجمه عن عدوي بكتيرية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن استخدام إمسيلتا في علاج العدوى البكتيرية للدم والتي قد تكون مرتبطة بنوع من العدوى المذكورة أعلاه.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستخدم إمسيلتا</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية تجاه إيميبينم ، سيلاستاتين أو اي من المكونات الأخرى لهذا الدواء (المدرجة في المادة 6)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية للمضادات الحيوية الأخرى مثل البنسلينات، الكيفالوسبورينات ، أو الكاربابينميات</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التحذيرات والاحتياطات </strong></p><p dir="RTL">تحدث إلى طبيبك أو الممرضة قبل استخدام إمسيلتا</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك حساسية لأي أدويه بما في ذلك المضادات الحيوية (الحساسية المفاجئة التي تهدد الحياة وتتطلب العلاج الطبي الفوري)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك التهاب القولون أو اي مرض معوي آخر</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك مشاكل في الكلي أو المسالك البولية، بما في ذلك انخفاض وظائف الكلي (ترتفع مستويات إمسيلتا في الدم في المرضي الذين يعانون من انخفاض وظائف الكلي. قد تحدث ردود فعل سلبيه للجهاز العصبي المركزي إذا لم يتم تعديل الجرعة بالنظر إلى وظائف الكلي)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك اي اضطرابات في الجهاز العصبي المركزي مثل الهزات الموضعية أو نوبات الصرع</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك مشاكل في الكبد</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن حدوث اختبار إيجابي (اختبار كومبس) الذي يشير إلى وجود أجسام مضادة التي قد تدمر خلايا الدم الحمراء. طبيبك سيناقش هذا معك</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>الأطفال </em></p><p dir="RTL">لا ينصح ب استخدام إمسيلتا في الأطفال الذين تقل أعمارهم عن سنه واحده أو الأطفال الذين يعانون من مشاكل في الكلي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأدويه الأخرى و إمسيلتا</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك، الصيدلي أو الممرضة إذا كنت تتناول أو تناولت أو تزمع أن تتناول أي أدوية أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك إذا كنت تتناول غانسيكلوفير التي يستخدم لعلاج بعض الالتهابات الفيروسية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أيضا، أخبر طبيبك إذا كنت تتناول حمض الفالبرويك أو فالبروات الصوديوم (المستخدمة لعلاج الصرع، واضطراب القطبين، والصداع النصفي، أو الفصام) أو اي من مسيلات الدم مثل الوارفارين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيقرر طبيبك ما إذا كان يجب عليك استخدام الدواء الذي تستخدمه المجموعة مع هذه الأدوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">إذا كنت حاملا أو مرضعة، تعتقدين بأنك قد تكوني حاملا أو تخططين للحمل، اطلبي من طبيبك تقديم المشورة قبل إعطاءك الدواء</p><p dir="RTL">&nbsp;</p><p dir="RTL">من المهم ان تخبري طبيبك إذا كنت حاملا أو تخطط للحمل قبل الحصول على إمسيلتا. ولم يتم دراسة استخدام إمسيلتا في النساء الحوامل. وينبغي ألا يستخدم إمسيلتا أثناء الحمل الا إذا قرر الطبيب ان الفائدة المحتملة تبرر الخطر المحتمل علي تطور الجنين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ومن المهم أن تخبري طبيبك إذا كنت تقومين بالرضاعة الطبيعية أو إذا كنت تنوين الرضاعة الطبيعية قبل الحصول على إمسيلتا. كميات صغيره من هذا الدواء قد تمر إلى حليب الثدي وقد يؤثر ذلك علي الطفل. ولذلك، سوف يقرر طبيبك ما إذا كان يجب عليك ان تستخدمين إيميبينم إمسيلتا في أثناء الرضاعة الطبيعية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">هناك بعض الآثار الجانبية المرتبطة بهذا المنتج (مثل الرؤية، السمع، أو الشعور بشيء غير موجود، والدوخة، والنعاس، والإحساس بالدوران) التي قد تؤثر في قدرة بعض المرضي علي قياده أو تشغيل آلات (انظر القسم 4).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إمسيلتا يحتوي علي الصوديوم</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">إمسيلتا 250 ملغ/250 ملغ يحتوي على 0.8 ملمول (18.8 ملغ) صوديوم لكل جرعة. إمسيلتا 500 ملغ/500 ملغ يحتوي على 1.6 ملمول (37.5 ملغ) صوديوم لكل جرعه.&nbsp; للأخذ في الاعتبار مع المرضي الخاضعين لحمية تحديد الصوديوم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سيتم اعداد إمسيلتا لإعطائه لك من قبل طبيبك أو ممارس صحي آخر. طبيبك سوف يقرر كم تحتاج من إيميبينم/سيلاستاتين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الاستخدام في البالغين والمراهقين </u></p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;الجرعة الموصي بها في للبالغين والمراهقين 500 ملغ/500 ملغ كل 6 ساعات أو 1,000 ملغ/1000 ملغ كل 6 أو 8 ساعات. إذا كان لديك مشاكل في الكلي طبيبك قد يخفض جرعتك</p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><u>الاستخدام في الأطفال</u></p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;الجرعة الخاصة بالأطفال الذين تبلغ أعمارهم سنه واحده أو أكثر هي 15/15 أو 25/25 ملغم/كغم/جرعه كل 6 ساعات. إمسيلتا لا ينصح به في الأطفال دون سنه واحده من العمر والأطفال الذين يعانون من مشاكل في الكلي.</p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><u>طريقه التناول </u></p><p dir="RTL">&nbsp;</p><p dir="RTL">يعطى إمسيلتا وريديا (في الوريد) على مدار 20-30 دقيقه للجرعة الأقل من أو المساوية ل 500 ملغ/500 ملغ أو على مدار 40-60 دقيقه للجرعة أكثر من 500 ملغ/500 ملغ. ويمكن إبطاء معدل التسريب إذا شعرت بالغثيان.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا كنت استخدمتر</strong><strong> إمسيلتا أكثر مما يجب </strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تشمل أعراض الجرعة المفرطة النوبات، والارتباك، والهزات، والغثيان، والقيء، وانخفاض ضغط الدم، وبطء معدل ضربات القلب. إذا كنت تشعر بالقلق بأنك قد أعطيت الكثير من إمسيلتا، اتصل بطبيبك أو أي ممارس صحي آخر على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا نسيت أن تتناول إمسيلتا</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">إذا كنت تشعر بالقلق بأنك نسيت تناول جرعة، اتصل بطبيبك أو أي ممارس صحي آخر على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تأخذ جرعة مضاعفة لتعوض جرعة منسية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن تناول إيميبينم إمسيلتا </strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتوقف عن استخدام إمسيلتا حتى يخبرك طبيبك بذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان لديك اي أسئلة أخرى حول استخدام هذا الدواء، أسال طبيبك أو الممرضة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل كل الأدويه ، هذا الدواء يمكن أن يسبب آثار جانبية، وإن لم يحصل الجميع عليها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الآثار الجانبية التالية تحدث نادرا، ولكن إذا حدثت أثناء أو بعد الحصول على إمسيلتا، يجب ان يوقف الدواء ويتم الاتصال بطبيبك على الفور.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحساسية بما في ذلك الطفح الجلدي، وتورم في الوجه والشفاه واللسان و/أو الحلق (مع صعوبة في التنفس أو البلع)، و/أو انخفاض ضغط الدم.<strong> </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقشير الجلد (التحلل الجلدي السمي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات جلديه حاده (متلازمة ستيفن-جونسون والحمامي المتعددة الأشكال)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي حاد مع فقدان الجلد والشعر (التهاب الجلد القشيري)</p><p dir="RTL">&nbsp;</p><p dir="RTL">الآثار الجانبية المحتملة الأخرى:</p><p dir="RTL"><strong>شائع </strong>(قد يؤثر على ما يصل إلى 1 من 10 أشخاص)</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غثيان، قيء، إسهال. ويظهر أن الغثيان والقيء أكثر تواترا في المرضي الذين يعانون من انخفاض عدد خلايا الدم البيضاء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم واحمرار على طول الوريد ويكون حساسا للغاية عندما يلمس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وظائف الكبد غير طبيعية في اختبارات الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في بعض خلايا الدم البيضاء</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائع</strong> (قد يؤثر على ما يصل إلى 1 من 100 شخص)</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار الجلد الموضعي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الألم الموضعي وتكون كتلة متماسكة في موقع الحقن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكه جلديه</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نتوءات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات الدم التي تؤثر على مكونات خلايا الدم والتي تكتشف عاده من قبل اختبارات الدم (قد تكون الاعراض التعب، شحوب الجلد، وكدمات طويلة بعد الإصابة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وظائف الكلي والكبد والدم غير طبيعية تكتشف في اختبارات الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الهزات والوخز غير المنضبط من العضلات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;التشنجات (الصرع)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات نفسيه (مثل تقلبات المزاج وضعف الحكم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الرؤية أو السمع أو الشعور بشيء ليس هناك (هلاوس)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتباك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوخة، النعاس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدم</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نادر </strong>(قد يؤثر على ما يصل إلى 1 من 1,000 شخص)</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوى الفطرية (الكانديدا)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تلطيخ الأسنان و/أو اللسان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب القولون مع الإسهال الشديد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات في التذوق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم قدره الكبد على أداء الوظائف العادية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الكبد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم قدره الكلية على أداء وظيفتها العادية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في كميه البول، وتغيرات في لون البول</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض المخ، وخز الإحساس (دبابيس والابر)، الهزة الموضعية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان السمع</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نادره جدا (</strong>قد تؤثر على ما يصل إلى 1 في 10,000 شخص)</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان حاد في وظائف الكبد بسبب الالتهاب (التهاب الكبد الفيروسي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المعدة أو الأمعاء (نزلة معوية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأمعاء مع الإسهال الدموي (التهاب القولون النزفي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم واحمرار اللسان، وفرط نمو من النتوءات العادية على اللسان مما يعطيه مظهرا مشعرا، حرقه، قرحه الحلق، وزيادة في إنتاج اللعاب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في المعدة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضجة الغزل (الدوار)، والصداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رنين في الاذنين (طنين)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في عده مفاصل، وضعف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم انتظام في نبضات القلب، القلب ينبض بقوة أو بسرعة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق في الصدر، صعوبة في التنفس، التنفس بشكل غير طبيعي سريع وسطحي، وألم في الجزء العلوي من العمود الفقري</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاحمرار، زرقان الوجه والشفاه، وتغيرات في نسيج الجلد، والتعرق المفرط</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة الفرج في النساء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التغيرات في كميات خلايا الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تدهور الامراض النادرة المرتبطة بضعف العضلات (تفاقم مرض الوهن العضلي الوبيل)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير معروف </strong><strong>(</strong>لا يمكن تقدير التكرار من البيانات المتوفرة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حركات غير طبيعية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الانفعال</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية </strong></p><p dir="RTL">إذا حدث لك أي آثار جانبيه، تحدث إلى طبيبك أو الممرضة. ويشمل ذلك أي اثار جانبيه محتملة غير مدرجة في هذه النشرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكنك أيضا الإبلاغ عن الآثار الجانبية مباشره عن طريق نظام الإبلاغ الوطني المدرج بالأسفل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المملكة العربية السعودية:</p><p dir="RTL"><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span dir=LTR></span><span
dir=LTR></span><span dir=LTR><span dir=LTR></span><span dir=LTR></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]--><!--[if gte vml 1]><v:shapetype id="_x0000_t202" coordsize="21600,21600"
 o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Text_x0020_Box_x0020_5" o:spid="_x0000_s1027"
 type="#_x0000_t202" style='width:207.65pt;height:62pt;visibility:visible;
 mso-wrap-style:square;mso-left-percent:-10001;mso-top-percent:-10001;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:char;
 mso-position-vertical:absolute;mso-position-vertical-relative:line;
 mso-left-percent:-10001;mso-top-percent:-10001;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="white [3201]" strokeweight=".5pt">
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal dir=RTL style='margin-bottom:0in;text-align:right;
    line-height:normal;direction:rtl;unicode-bidi:embed'><span lang=AR-SA
    style='font-family:"Arial",sans-serif;mso-ascii-font-family:Calibri;
    mso-ascii-theme-font:minor-latin;mso-hansi-font-family:Calibri;mso-hansi-theme-font:
    minor-latin;mso-bidi-theme-font:minor-bidi'>المركز الوطني للتيقظ الدوائي:<o:p></o:p></span></p>
    <p class=MsoNormal dir=RTL style='margin-bottom:0in;text-align:right;
    line-height:normal;direction:rtl;unicode-bidi:embed'><span lang=AR-SA
    style='font-family:"Arial",sans-serif;mso-ascii-font-family:Calibri;
    mso-ascii-theme-font:minor-latin;mso-hansi-font-family:Calibri;mso-hansi-theme-font:
    minor-latin;mso-bidi-theme-font:minor-bidi'>مركز االتصال الموحد: 19999 </span><span
    dir=LTR><o:p></o:p></span></p>
    <p class=MsoNormal dir=RTL style='margin-bottom:0in;text-align:right;
    line-height:normal;direction:rtl;unicode-bidi:embed'><span lang=AR-SA
    style='font-family:"Arial",sans-serif;mso-ascii-font-family:Calibri;
    mso-ascii-theme-font:minor-latin;mso-hansi-font-family:Calibri;mso-hansi-theme-font:
    minor-latin;mso-bidi-theme-font:minor-bidi'>البريد الإلكتروني: </span><a
    href="mailto:npc.drug@sfda.gov.sa"><span dir=LTR>npc.drug@sfda.gov.sa</span></a><span
    dir=LTR><o:p></o:p></span></p>
    <p class=MsoNormal dir=RTL style='margin-bottom:0in;text-align:right;
    line-height:normal;direction:rtl;unicode-bidi:embed'><span lang=AR-SA
    style='font-family:"Arial",sans-serif;mso-ascii-font-family:Calibri;
    mso-ascii-theme-font:minor-latin;mso-hansi-font-family:Calibri;mso-hansi-theme-font:
    minor-latin;mso-bidi-theme-font:minor-bidi'>الموقع الإلكتروني: </span><a
    href="https://ade.sfda.gov.sa"><span dir=LTR>https://ade.sfda.gov.sa</span></a><span
    lang=AR-SA style='font-family:"Arial",sans-serif;mso-ascii-font-family:
    Calibri;mso-ascii-theme-font:minor-latin;mso-hansi-font-family:Calibri;
    mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-bidi'><o:p></o:p></span></p>
    <p class=MsoNormal dir=RTL style='margin-bottom:0in;text-align:right;
    line-height:normal;direction:rtl;unicode-bidi:embed'><span dir=LTR></span><span
    lang=AR-SA dir=LTR><span dir=LTR></span><span
    style='mso-spacerun:yes'> </span></span><span dir=LTR><o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:shape><![endif]--></p><p dir="RTL">المركز الوطني للتيقظ الدوائي:</p><p dir="RTL">مركز االتصال الموحد: 19999</p><p dir="RTL">البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">الموقع الإلكتروني: https://ade.sfda.gov.sa</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;دول الخليج العربي الأخرى:</p><p>الرجاء الإتصال بالجهات الوطنية في كل دولة</p><p dir="RTL">بالإبلاغ عن الآثار الجانبية يمكنك المساعدة في توفير المزيد من المعلومات عن سلامه هذا الدواء.</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احتفظ بهذا الدواء بعيدا عن مرأى ومتناول الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية الذي يرد على الملصق بعد EXP. يشير تاريخ انتهاء الصالحية إلى آخر يوم من ذلك الشهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قبل الفتح:</p><p dir="RTL">لا تخزن فوق 25 درجه مئوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بعد الفتح الأول/ تجهيز المحلول:</p><p dir="RTL">يجب استخدام المحلول المجهز/المخفف فورا. وينبغي الا تتجاوز الفترة الزمنية الفاصلة بين بداية أعاده التشكيل ونهاية التسريب الوريدي ساعتين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تجمد المحلول المجهز.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلص من اي دواء عن طريق الصرف الصحي أو النفايات المنزلية. أسال الصيدلي الخاص بك كيفية التخلص من الأدوية التي لم تعد تستخدمها. ستساعد هذه التدابير على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المواد الفعالة هي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 500 ملغ من إيميبينم (على شكل 530 ملغ من إيميبينم مونوهيدرات) و500 ملغ سيلاستاتين (على شكل 530 ملغ من ملح صوديوم السيلاستاتين)</p><p dir="RTL">&nbsp;</p><p dir="RTL">العنصر الآخر هو كربونات هيدروجين الصوديوم</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>كيف يبدو إمسيلتا ومحتويات العبوة:</strong></p><p dir="RTL">إمسيلتا 500 ملغ إيميبينم و500 ملغ سيلاستاتين هو مسحوق ابيض إلى مائل للبياض أو اصفر تقريبا معبأ في 20 مل قوارير زجاجية زجاجات 100 مل زجاجية.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">فرينيوس كابي دويتشلاند جي إم بي إتش</p><p dir="RTL">&nbsp;</p><p dir="RTL">المصنع:</p><p dir="RTL">ايه سي أس دوبفار إس بي ايه ، نيوكليو انداستريال إس. أتو ، إس. نيكولوا توردينو ، تيرامو ، إيطاليا</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            05/2016
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Imipenem/Cilastatin Kabi 500 mg/500 mg, powder for solution for infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Imipenem/Cilastatin Kabi 500 mg/500 mg, powder for solution for infusion 
Each vial/bottle contains imipenem monohydrate equivalent to 500 mg imipenem
anhydrate and cilastatin sodium equivalent to 500 mg cilastatin.

Excipient(s) with known effect:
Each vial/bottle contains sodium bicarbonate equivalent to approximately 1.6 mEq of
sodium (approximately 37.5 mg)
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder for solution for infusion.
White to almost white or light yellow powder.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Imipenem/Cilastatin Kabi is indicated for the treatment of the following infections in<br />adults and children 1 year of age and above (see section 4.4 and 5.1):</p><ul><li>complicated intra-abdominal infections</li><li>severe pneumonia including hospital and ventilator-associated pneumonia</li><li>intra- and post-partum infections</li><li>complicated urinary tract infections</li><li>complicated skin and soft-tissue infections.</li></ul><p>Imipenem/Cilastatin Kabi may be used in the management of neutropenic patients with<br />fever that is suspected to be due to a bacterial infection.<br />Treatment of patients with bacteraemia that occurs in association with, or is suspected<br />to be associated with, any of the infections listed above.<br />Consideration should be given to official guidance on the appropriate use of<br />antibacterial agents.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology<br />The dose recommendations for Imipenem/Cilastatin Kabi represent the quantity of<br />imipenem/cilastatin to be administered.<br />The daily dose of Imipenem/Cilastatin Kabi should be based on the type of infection<br />and given in equally divided doses based on consideration of degree of susceptibility<br />of the pathogen(s) and the patient&#39;s renal function (see also section 4.4 and 5.1).<br />Adults and adolescents<br />For patients with normal renal function (creatinine clearance of &gt;90 ml/min), the<br />recommended dose regimens are:<br />500 mg/500 mg every 6 hours OR<br />1000 mg/1000 mg every 8 hours OR every 6 hours<br />It is recommended that infections suspected or proven to be due to less susceptible<br />bacterial species (such as Pseudomonas aeruginosa) and very severe infections (e.g. in<br />neutropenic patients with a fever) should be treated with 1000 mg/1000 mg<br />administered every 6 hours.<br />A reduction in dose is necessary when:<br />creatinine clearance is &le; 90 ml/min/(see Table 1)<br />The maximum total daily dose should not exceed 4000 mg/4000 mg per day.<br />Patients with renal impairment<br />To determine the reduced dose for adults with impaired renal function:<br />1. The total daily dose (i.e. 2000/2000, 3000/3000 or 4000/4000 mg) that would<br />usually be applicable to patients with normal renal function should be selected.<br />2. From table 1 the appropriate reduced dose regimen is selected according to the<br />patient&#39;s creatinine clearance. For infusion times see Method of administration.<br /><br />Table 1:</p><table border="1" cellspacing="1" cellpadding="1" style="width:478px"><tbody><tr><td style="width:119px">Creatinine<br />Clearance (mL/min)<br />is:</td><td style="width:117px">If TOTAL DAILY DOSE is: 2000 mg/day</td><td style="width:96px">If TOTAL DAILY DOSE is: 3000 mg/day</td><td style="width:143px">If TOTAL DAILY DOSE is: 4000 mg/day</td></tr><tr><td style="width:119px">&ge;90 (normal)</td><td style="width:117px">500 &nbsp;q6h</td><td style="width:96px">1000 q8h</td><td style="width:143px">1000 q6h</td></tr><tr><td style="width:119px">&nbsp;</td><td style="width:117px">&nbsp;</td><td style="width:96px">&nbsp;</td><td style="width:143px">&nbsp;</td></tr></tbody></table><p>reduced dosage (mg) for patients with renal impairment:</p><p><br />Patients with a creatinine clearance of &lt;15 ml/min<br />These patients should not receive Imipenem/Cilastatin Kabi unless haemodialysis is<br />instituted within 48 hours.<br />Patients on haemodialysis<br />When treating patients with creatinine clearances of &lt;15 ml/min who are undergoing<br />dialysis use the dose recommendation for patients with creatinine clearances of 15 to<br />29 ml/min (see table 1).<br />Both imipenem and cilastatin are cleared from the circulation during haemodialysis.<br />The patient should receive Imipenem/Cilastatin Kabi after haemodialysis and at 12<br />hour intervals timed from the end of that haemodialysis session. Dialysis patients,<br />especially those with background central nervous system (CNS) disease, should be<br />carefully monitored; for patients on haemodialysis, Imipenem/Cilastatin Kabi is<br />recommended only when the benefit outweighs the potential risk of seizures (see<br />section 4.4).<br />Currently there are inadequate data to recommend use of Imipenem/Cilastatin Kabi for<br />patients on peritoneal dialysis.<br />Patients with hepatic impairment<br />No dose adjustment is recommended in patients with impaired hepatic function (see<br />section 5.2).<br />Elderly people<br />No dose adjustment is required for older people with normal renal function (see<br />section 5.2).<br />Paediatric population &ge;1 year of age<br />For paediatric patients &ge;1 year of age, the recommended dose is 15/15 or 25/25<br />mg/kg/dose administered every 6 hours.<br />It is recommended that infections suspected or proven to be due to less susceptible<br />bacterial species (such as Pseudomonas aeruginosa) and very severe infections (e.g.<br /><br />in neutropenic patients with a fever) should be treated with 25/25 mg/kg administered<br />every 6 hours.<br />Paediatric population &lt;1 year of age<br />Clinical data are insufficient to recommend dosing for children less than 1 year of age<br />Paediatric population with renal impairment<br />Clinical data are insufficient to recommend dosing for paediatric patients with renal<br />impairment (serum creatinine &gt; 2 mg/dl). See section 4.4.<br />Method of administration<br />Imipenem/Cilastatin Kabi is to be reconstituted and further diluted (see section 6.2, 6.3<br />and 6.6) prior to administration. Each dose of &le; 500 mg/500 mg should be given by<br />intravenous infusion over 20 to 30 minutes. Each dose &gt;500 mg/500 mg should be<br />infused over 40 to 60 minutes. In patients who develop nausea during the infusion, the<br />rate of infusion may be slowed.<br />For instructions on reconstitution of the medicinal product before administration, see section<br />6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance(s) or to any of the excipients listed in section 6.1 Hypersensitivity to any other carbapenem antibacterial agent Severe  hypersensitivity  (e.g.  anaphylactic  reaction,  severe  skin  reaction)  to any  other  type  of  beta-lactam  antibacterial  agent  (e.g.  penicillins  or cephalosporins).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The &nbsp;selection &nbsp;of &nbsp;imipenem/cilastatin &nbsp;to &nbsp;treat &nbsp;an &nbsp;individual &nbsp;patient &nbsp;should &nbsp;take &nbsp;into account the appropriateness of using a carbapenem antibacterial agent based on factors such &nbsp;as &nbsp;severity &nbsp;of &nbsp;the &nbsp;infection, &nbsp;the &nbsp;prevalence &nbsp;of &nbsp;resistance &nbsp;to &nbsp;other &nbsp;suitable antibacterial agents and the risk of selecting for carbapenem-resistant bacteria.Hypersensitivity Serious &nbsp;and &nbsp;occasionally &nbsp;fatal &nbsp;hypersensitivity &nbsp;(anaphylactic) &nbsp;reactions &nbsp;have &nbsp;been reported &nbsp;in &nbsp;patients &nbsp;receiving &nbsp;therapy &nbsp;with &nbsp;beta-lactams. &nbsp;These &nbsp;reactions &nbsp;are &nbsp;more likely to occur in individuals with a history of sensitivity to multiple allergens. Before initiating &nbsp;therapy &nbsp;with &nbsp;Imipenem/Cilastatin &nbsp;Kabi, &nbsp;careful &nbsp;inquiry &nbsp;should &nbsp;be &nbsp;made concerning &nbsp;previous &nbsp;hypersensitivity &nbsp;reactions &nbsp;to &nbsp;carbapenems, &nbsp;penicillins, cephalosporins, other beta-lactams and other allergens (see section 4.3). If an allergic reaction &nbsp;to &nbsp;Imipenem/Cilastatin &nbsp;Kabi &nbsp;occurs, &nbsp;discontinue &nbsp;the &nbsp;therapy &nbsp;immediately. Serious anaphylactic reactions require immediate emergency treatment.Hepatic &nbsp; Hepatic &nbsp;function &nbsp;should &nbsp;be &nbsp;closely &nbsp;monitored &nbsp;during &nbsp;treatment &nbsp;with imipenem/cilastatin &nbsp;due &nbsp;to &nbsp;the &nbsp;risk &nbsp;of &nbsp;hepatic &nbsp;toxicity &nbsp;(such &nbsp;as &nbsp;increase &nbsp;in transaminases, hepatic failure and fulminant hepatitis).</p><p>Use &nbsp;in &nbsp;patients &nbsp;with &nbsp;liver &nbsp;disease: &nbsp;patients &nbsp;with &nbsp;pre-existing &nbsp;liver &nbsp;disorders &nbsp;should have liver function monitored during treatment with imipenem/cilastatin. There is no dose adjustment necessary (see section 4.2).</p><p>Haematology A positive direct or indirect Coombs test may develop during treatment with imipenem/cilastatin.</p><p>Antibacterial spectrum The &nbsp;antibacterial &nbsp;spectrum &nbsp;of &nbsp;imipenem/cilastatin &nbsp;should &nbsp;be &nbsp;taken &nbsp;into &nbsp;account especially &nbsp;in &nbsp;life-threatening &nbsp;conditions &nbsp;before &nbsp;embarking &nbsp;on &nbsp;any &nbsp;empiric &nbsp;treatment. Furthermore, &nbsp;due &nbsp;to &nbsp;the &nbsp;limited &nbsp;susceptibility &nbsp;of &nbsp;specific &nbsp;pathogens &nbsp;associated &nbsp;with e.g. bacterial skin and soft-tissue infections, to imipenem/cilastatin, caution should be exercised. The use of imipenem/cilastatin is not suitable for treatment of these types of infections unless the pathogen is already documented and known to be susceptible or there is &nbsp;a very high suspicion that the most likely pathogen(s) would be suitable for treatment. &nbsp;Concomitant &nbsp;use &nbsp;of &nbsp;an &nbsp;appropriate &nbsp;anti-MRSA &nbsp;agent &nbsp;may &nbsp;be &nbsp;indicated when &nbsp;MRSA &nbsp;infections &nbsp;are &nbsp;suspected &nbsp;or &nbsp;proven &nbsp;to &nbsp;be &nbsp;involved &nbsp;in &nbsp;the &nbsp;approved indications. &nbsp;Concomitant &nbsp;use &nbsp;of &nbsp;an &nbsp;aminoglycoside &nbsp;may &nbsp;be &nbsp;indicated &nbsp;when Pseudomonas &nbsp;aeruginosa &nbsp;infections &nbsp;are &nbsp;suspected &nbsp;or &nbsp;proven &nbsp;to &nbsp;be &nbsp;involved &nbsp;in &nbsp;the approved indications (see section 4.1).</p><p>Interaction with valproic acid The concomitant use of imipenem/cilastatin and valproic acid/sodium valproate is not recommended (see section 4.5).</p><p>Clostridium difficile Antibiotic-associated &nbsp;colitis &nbsp;and pseudomembranous &nbsp;colitis have been &nbsp;reported &nbsp;with imipenem/ &nbsp;cilastatin &nbsp;and &nbsp;with &nbsp;nearly &nbsp;all &nbsp;other &nbsp;anti-bacterial &nbsp;agents &nbsp;and &nbsp;may &nbsp;range from mild to life-threatening in severity. It is important to consider this diagnosis in patients &nbsp;who &nbsp;develop &nbsp;diarrhoea &nbsp;during &nbsp;or &nbsp;after &nbsp;the &nbsp;use &nbsp;of &nbsp;imipenem/cilastatin &nbsp;(see section &nbsp;4.8). &nbsp;Discontinuation &nbsp;of &nbsp;therapy &nbsp;with &nbsp;imipenem/cilastatin &nbsp;and &nbsp;the administration &nbsp;of &nbsp;specific &nbsp;treatment &nbsp;for &nbsp;Clostridium &nbsp;difficile &nbsp;should &nbsp;be &nbsp;considered. Medicinal products that inhibit peristalsis should not be given.</p><p>Meningitis &nbsp; Imipenem/Cilastatin Kabi is not recommended for the therapy of meningitis.</p><p>Renal impairment Imipenem-cilastatin &nbsp;accumulates &nbsp;in &nbsp;patients &nbsp;with &nbsp;reduced &nbsp;kidney &nbsp;function. &nbsp;CNS adverse &nbsp;reactions &nbsp;may &nbsp;occur &nbsp;if &nbsp;the &nbsp;dose &nbsp;is &nbsp;not &nbsp;adjusted &nbsp;to &nbsp;the &nbsp;renal &nbsp;function, &nbsp;see section 4.2 and 4.4 &ldquo;Central nervous system&rdquo; in this section.</p><p>Central nervous system:</p><p>CNS adverse reactions such as myoclonic activity, confusional states, or seizures have been reported, especially when recommended doses based on renal function and body weight &nbsp;were &nbsp;exceeded. &nbsp;These &nbsp;experiences &nbsp;have &nbsp;been &nbsp;reported &nbsp;most &nbsp;commonly &nbsp;in patients &nbsp;with &nbsp;CNS &nbsp;disorders &nbsp;(e.g. &nbsp;brain &nbsp;lesions &nbsp;or &nbsp;history &nbsp;of &nbsp;seizures) &nbsp;and/or compromised renal function in whom accumulation of the administered entities could occur. Hence close adherence to recommended dose schedules is urged especially in these patients (see section 4.2). Anticonvulsant therapy should be continued in patients with a known seizure disorder.</p><p>Special &nbsp;awareness &nbsp;should &nbsp;be &nbsp;made &nbsp;to &nbsp;neurological &nbsp;symptoms &nbsp;or &nbsp;convulsions &nbsp;in children &nbsp;with &nbsp;known &nbsp;risk &nbsp;factors &nbsp;for &nbsp;seizures, &nbsp;or &nbsp;on &nbsp;concomitant &nbsp;treatment &nbsp;with medicinal products lowering the seizures threshold.</p><p>If focal tremors, myoclonus or seizures occur, patient should be evaluated<br />neurologically and placed on anticonvulsant therapy if not already instituted. If CNS<br />symptoms continue, the dose of Imipenem/Cilastatin Kabi should be decreased or<br />discontinued.<br />Patients with creatinine clearances of &lt;15 ml/min should not receive<br />Imipenem/Cilastatin Kabi unless haemodialysis is instituted within 48 hours. For<br />patients on haemodialysis, Imipenem/Cilastain Kabi is recommended only when the<br />benefit outweighs the potential risk of seizures (see section 4.2)<br />Paediatric population<br />Clinical data are insufficient to recommend the use of Imipenem/Cilastatin Kabi in<br />children under 1 year of age or paediatric patients with impaired renal function (serum<br />creatinine &gt;2 mg/dl). See also above under Central nervous system.<br />sodium per vial/bottle which should be taken into consideration by patients on a<br />controlled sodium diet.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Generalized seizures have been reported in patients who received ganciclovir and<br />imipenem/cilastatin. These medicinal products should not be used concomitantly<br />unless the potential benefit outweighs the risks.<br />Decreases in valproic acid levels that may fall below the therapeutic range have been<br />reported when valproic acid was co-administered with carbapenem agents. The<br />lowered valproic acid levels can lead to inadequate seizure control; therefore,<br />concomitant use of imipenem and valproic acid/sodium valproate is not recommended<br />and alternative antibacterial or anti-convulsant therapies should be considered (see<br />section 4.4).<br />Oral anti-coagulants<br />Simultaneous administration of antibiotics with warfarin may augment its anti-<br />coagulant effects.<br /><br />There have been many reports of increases in the anti-coagulant effects of orally<br />administered anti-coagulant agents, including warfarin in patients who are<br />concomitantly receiving antibacterial agents. The risk may vary with the underlying<br />infection, age and general status of the patient so that the contribution of the antibiotic<br />to the increase in INR (international normalised ratio) is difficult to assess. It is<br />recommended that the INR should be monitored frequently during and shortly after coadministration<br />of antibiotics with an oral anti-coagulant agent.<br />Concomitant administration of imipenem/cilastatin and probenecid resulted in minimal<br />increases in the plasma levels and plasma half-life of imipenem. The urinary recovery<br />of active (non-metabolized) imipenem decreased to approximately 60% of the dose<br />when imipenem/cilastatin was administered with probenecid. Concomitant<br />administration of imipenem/cilastatin and probenecid doubled the plasma level and<br />half-life of cilastatin, but had no effect on urine recovery of cilastatin.<br />Paediatric population<br />Interaction studies have only been performed in adults.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />There are no adequate and well-controlled studies for the use of imipenem/ cilastatin<br />in pregnant women.<br />Studies in pregnant monkeys have shown reproductive toxicity (see section 5.3). The<br />potential risk for humans is unknown.<br />Imipenem/Cilastatin Kabi should be used during pregnancy only if the potential<br />benefit justifies the potential risk to the foetus<br />Breast-feeding<br />Imipenem and cilastatin are excreted into the mother&rsquo;s milk in small quantities. Little<br />absorption of either compound occurs following oral administration. Therefore it is<br />unlikely that the suckling infant will be exposed to significant quantities. If the use of<br />Imipenem/Cilastatin Kabi is deemed necessary, the benefit of breast feeding for the<br />child should be weighed against the possible risk for the child.<br />Fertility<br />There are no data available regarding potential effects of imipenem/cilastatin<br />treatment on male or female fertility.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been<br />performed. However, there are some side effects (such as hallucination, dizziness,<br />somnolence, and vertigo) associated with this product that may affect some patients&rsquo;<br />ability to drive or operate machinery (see section 4.8).<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In clinical trials including 1,723 patients treated with imipenem/cilastatin intravenous<br />the most frequently reported systemic adverse reactions that were reported at least<br />possibly related to therapy were nausea (2.0%), diarrhoea (1.8%), vomiting (1.5%),<br />rash (0.9%), fever (0.5%), hypotension (0.4%), seizures (0.4%) (see section 4.4),<br />dizziness (0.3%), pruritus (0.3%), urticaria (0.2%), somnolence (0.2%). Similarly, the<br />most frequently reported local adverse reactions were phlebitis/thrombophlebitis<br />(3.1%), pain at the injection site (0.7%), erythema at the injection site (0.4%) and vein<br />induration (0.2%). Increases in serum transaminases and in alkaline phosphatase are<br />also commonly reported.<br />The following adverse reactions have been reported in clinical studies or during postmarketing<br />experience.<br />All adverse reactions are listed under system organ class and frequency: Very<br />common (&ge;1/10), Common (&ge;1/100 to &lt;1/10), Uncommon (&ge;1/1,000 to &lt;1/100), Rare<br />(&ge;1/10,000 to &lt;1/1,000), Very rare (&lt;1/10,000) and not known (cannot be estimated<br />from the available data).<br />Within each frequency grouping, undesirable effects are presented in order of<br />decreasing seriousness.<br />System Organ Class Frequency Event<br />Infections and infestations Rare pseudomembranous colitis, candidiasis<br />Very rare gastro-enteritis<br />Blood and lymphatic system<br />disorders<br />Common eosinophilia<br />Uncommon pancytopenia, neutropenia, leucopenia,<br />thrombocytopenia, thrombocytosis<br />Rare agranulocytosis<br />Very rare haemolytic anaemia, bone marrow<br />depression<br />Immune system disorders Rare anaphylactic reactions<br />Psychiatric disorders Uncommon psychic disturbances including<br />hallucinations and confusional states<br />Nervous system disorders Uncommon seizures, myoclonic activity, dizziness,<br />somnolence<br />Rare encephalopathy, paraesthesia, focal<br />tremor, taste perversion<br />Very rare aggravation of myasthenia gravis,<br />headache<br />Not known agitation, dyskinesia<br />Ear and labyrinth disorders Rare hearing loss<br />Very rare vertigo, tinnitus<br />Cardiac disorders Very rare cyanosis, tachycardia, palpitations<br />Vascular disorders Common thrombophlebitis<br />Uncommon hypotension<br />Very rare flushing<br />Respiratory, thoracic and Very rare dyspnoea, hyperventilation,<br /><br />mediastinal disorders pharyngeal pain<br />Gastrointestinal disorders Common diarrhoea, vomiting, nausea<br />Medicinal product-related nausea<br />and/or vomiting appear to occur more<br />frequently in granulocytopenic patients<br />than in non-granulocytopenic patients<br />treated with imipenem/cilastatin<br />Rare staining of teeth and/or tongue<br />Very rare haemorrhagic colitis, abdominal pain,<br />heartburn, glossitis, tongue papilla<br />hypertrophy, increased salivation<br />Hepatobiliary disorders Rare hepatic failure, hepatitis<br />Very rare fulminant hepatitis<br />Skin and subcutaneous<br />tissue disorders<br />Musculoskeletal and<br />connective tissue disorders<br />Common rash (e.g. exanthematous)<br />Uncommon urticaria, pruritus<br />Rare toxic epidermal necrolysis,<br />angioedema, Stevens-Johnson<br />syndrome, erythema multiforme,<br />exfoliative dermatitis<br />Very rare hyperhidrosis, skin texture changes<br />Very rare polyarthralgia, thoracic spine pain<br />Renal and urinary disorders Rare acute renal failure, oligurial/anuria,<br />polyuria, urine discoloration (harmless<br />and should not be confused with<br />haematuria)<br />The role of imipenem/cilastatin in<br />changes in renal function is difficult to<br />assess, since factors predisposing to prerenal<br />azotemia or to impaired renal<br />function usually have been present.<br />Reproductive system and Very rare pruritus vulvae<br />breast disorders<br />General disorders and Uncommmon fever, local pain and induration at the<br />administration site injection site, erythema at the injection<br />conditions site<br />Very rare chest discomfort, asthenia/weakness<br />Investigations Common increases in serum transaminases,<br />increases in serum alkaline<br />phosphatase<br />Uncommon a positive direct Coombs&#39; test,<br />prolonged prothrombin time,<br />decreased haemoglobin, increases in<br />serum bilirubin, elevations in serum<br />creatinine, elevations in blood urea<br />nitrogen<br />Paediatric population (&ge;3 months of age)<br /><br />In studies of 178 paediatric patients &ge;3 months of age, the reported adverse reactions were<br />consistent with those reported for adults.<br />Reporting of suspected adverse reactions<br />Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows<br />continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are<br />asked to report any suspected adverse reactions via the national reporting system listed below:<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Symptoms of overdose that can occur are consistent with the adverse reaction profile;<br />these may include seizures, confusion, tremors, nausea, vomiting, hypotension,<br />bradycardia. No specific information is available on treatment of overdose with<br />Imipenem/Cilastatin Kabi. Imipenem - cilastatin sodium are haemodialysable.<br />However, usefulness of this procedure in the overdosage setting is unknown</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antibacterials for systemic use, carbapenems.ATC code:<br />J01D H51<br />Mechanism of action Mode of action<br />Imipenem/Cilastatin Kabi consists of two components: imipenem and cilastatin<br />sodium in a 1:1 ratio by weight.<br />Imipenem, also referred to as N-formimidoyl-thienamycin, is a semi-synthetic<br />derivative of thienamycin, the parent compound produced by the filamentous<br />bacterium Streptomyces cattleya.<br />Imipenem exerts its bactericidal activity by inhibiting bacterial cell wall synthesis in<br />Gram-positive and Gram-negative bacteria through binding to penicillin-binding<br />proteins (PBPs).<br />Cilastatin sodium is a competitive, reversible and specific inhibitor of<br />dehydropeptidase-I, the renal enzyme which metabolizes and inactivates imipenem. It<br />is devoid of intrinsic antibacterial activity and does not affect the antibacterial activity<br />of imipenem.<br />Pharmacokinetic/Pharmacodynamic (PK/PD) relationship<br />Similar to other beta-lactam antibacterial agents, the time that imipenem<br />concentrations exceed the MIC (T&gt;MIC) has been shown to best correlate with<br />efficacy.<br />Mechanism/s of Resistance<br />Resistance to imipenem may be due to the following:<br />10(17)<br />Decreased permeability of the outer membrane of Gram-negative bacteria (due to<br />diminished production of porins)<br />Imipenem may be actively removed from the cell with an efflux pump.<br />Reduced affinity of PBPs to imipenem<br />Imipenem is stable to hydrolysis by most beta-lactamases, including penicillinases and<br />cephalosporinases produced by gram-positive and gram-negative bacteria, with the<br />exception of relatively rare carbapenem hydrolysing beta-lactamases. Species resistant<br />to other carbapenems do generally express co-resistance to imipenem. There is no<br />target-based cross-resistance between imipenem and agents of the quinolone,<br />aminoglycoside, macrolide and tetracycline classes.<br />Breakpoints<br />EUCAST MIC breakpoints for imipenem to separate susceptible (S) pathogens from resistant<br />(R) pathogens are as follows (v 1,1 2010-04-27):<br />Enterobacteriaceae<br />1<br />: S &le; 2 mg/l, R &gt;8 mg/l<br />Pseudomonas spp.<br />2<br />: S &le;4 mg/l, R &gt;8 mg/l<br />Acinetobacter spp.: S &le;2 mg/l, R &gt;8 mg/l<br />Staphylococcus spp.<br />3<br />: Inferred from cefoxitin susceptibility<br />Enterococcus spp.: S &le;4 mg/l, R &gt;8 mg/l<br />Streptococcus A, B, C, G: The beta-lactam susceptibility of beta-haemolytic<br />streptococcus groups A, B, C and G is inferred from the penicillin susceptibility.<br />Streptococcus pneumoniae<br />4<br />: S &le;2 mg/l, R &gt;2 mg/l<br />Other streptococci<br />4<br />: S &le;2 mg/l, R &gt;2 mg/l<br />Haemophilus influenzae<br />4<br />: S &le;2 mg/l, R &gt;2 mg/l<br />Moraxalla catarrhalis<br />4<br />: S &le;2 mg/l, R &gt;2 mg/l<br />Neisseria gonorrhoeae: There is insufficient evidence that Neisseria gonorrhoeae is a<br />good target for therapy with imipenem.<br />Gram-positive anaerobes: S &le;2 mg/l, R &gt;8 mg/l<br />Gram-negative anaerobes: S &le;2 mg/l, R &gt;8 mg/l<br />Non-species related breakpoints<br />5<br />: S &le;2 mg/l, R &gt;8 mg/l<br />1Proteus and Morganella species are considered poor targets for imipenem.<br />2The breakpoints for Pseudomonas relate to high dose frequent therapy (1g every 6 hours).<br />3Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.<br />4Strains with MIC values above the susceptible breakpoint are very rare or not yet reported.<br />The identification and antimicrobial susceptibility tests on any such isolate must be repeated<br />and if the result is confirmed the isolate must be sent to a reference laboratory. Until there is<br />evidence regarding clinical response for confirmed isolates with MIC above the current<br />resistant breakpoint they should be reported resistant.<br />5Non- species related breakpoint have been determined mainly on the basis of PK/PD data and<br />are independent of MIC distributions of specific species. They are for use only for species not<br />mentioned in the overview of species-related breakpoints or footnotes.<br />Susceptibility<br />The prevalence of acquired resistance may vary geographically and with time for<br />selected species and local information on resistance is desirable, particularly when<br />treating severe infections. As necessary, expert advice should be sought when the local<br />prevalence of resistance is such that the utility of the agent in at least some types of<br />infections is questionable.<br />Commonly susceptible species:<br />11(17)<br />Gram-positive aerobes:<br />Enterococcus faecalis<br />*<br />Staphylococcus aureus (Methicillin-susceptible)<br />Staphylococcus coagulase negative (Methicillin-susceptible)<br />Streptococcus agalactiae<br />Streptococcus pneumoniae<br />Streptococcus pyogenes<br />Streptococcus viridans group<br />Gram-negative aerobes:<br />Citrobacter freundii<br />Enterobacter aerogenes<br />Enterobacter cloacae<br />Escherichia coli<br />Haemophilus influenzae<br />Klebsiella oxytoca<br />Klebsiella pneumoniae<br />Moraxella catarrhalis<br />Serratia marcescens<br />Gram-positive anaerobes:<br />**<br />Clostridium perfringens<br />**<br />Peptostreptococcus spp.<br />Gram-negative anaerobes:<br />Bacteroides fragilis<br />Bacteroides fragilis group<br />Fusobacterium spp.<br />Porphyromonas asaccharolytica<br />Prevotella spp.<br />Veillonella spp.<br />Species for which acquired resistance may be a problem:<br />Gram-negative aerobes:<br />Acinetobacter baumannii<br />Pseudomonas aeruginosa<br />Inherently resistant species:<br />Gram positive aerobes:<br />Enterococcus faecium<br />Gram negative aerobes:<br />Some strains of Burkholderia cepacia (formerly Pseudomonas cepacia)<br />Legionella spp.<br />Stenotrophomonas maltophilia (formerly Xanthomonas maltophilia, formerly<br />Pseudomonas maltophilia)<br />Others:<br />Chlamydia spp.<br />Chlamydophila spp.<br />Mycoplasma spp.<br />Ureoplasma urealyticum<br />All methicillin-resistant staphylococci are resistant to imipenem/cilastatin.<br />**<br />EUCAST non-species related breakpoint is used.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Imipenem<br />AbsorptionIn normal volunteers, intravenous infusion of imipenem/cilastatin over 20<br />minutes resulted in peak plasma levels of imipenem ranging from 12 to 20 jig/ml for<br />the 250 mg/250 mg dose, from 21 to 58 jig/ml for the 500 mg/500 mg dose, and from<br />41 to 83 jig/ml for the 1000 mg/1000 mg dose. The mean peak plasma levels of<br />imipenem following the 250 mg/250 mg, 500 mg/500 mg, and 1000 mg /1000 mg<br />doses were 17, 39, and 66 jig/ml, respectively. At these doses, plasma levels of<br />imipenem decline to below 1 jig/ml or less in four to six hours.<br />Distribution<br />The binding of imipenem to human serum proteins is approximately 20%.<br />Biotransformation<br />When administered alone, imipenem is metabolized in the kidneys by<br />dehydropeptidase-I. Individual urinary recoveries ranged from 5 to 40%, with an<br />average recovery of 15-20% in several studies.<br />Cilastatin is a specific inhibitor of dehydropeptidase-I enzyme and effectively inhibits<br />metabolism of imipenem so that concomitant administration of imipenem and<br />cilastatin allows therapeutic antibacterial levels of imipenem to be attained in both<br />urine and plasma.<br />Elimination<br />The plasma half-life of imipenem was one hour. Approximately 70% of the<br />administered antibiotic was recovered intact in the urine within ten hours, and no<br />further urinary excretion of imipenem was detectable. Urine concentrations of<br />imipenem exceeded 10 jig/ml for up to eight hours after a 500 mg/500 mg dose of<br />imipenem/cilastatin. The remainder of the administered dose was recovered in the<br />urine as antibacterially inactive metabolites, and faecal elimination of imipenem was<br />essentially nil.<br />No accumulation of imipenem in plasma or urine has been observed with regimens of<br />imipenem/cilastatin, administered as frequently as every six hours, in patients with<br />normal renal function.<br />Cilastatin<br />Absorption<br />Peak plasma levels of cilastatin, following a 20 minute intravenous infusion of<br />imipenem/cilastatin, ranged from 21 to 26 jig/ml for the 250 mg/250 mg dose, from 21<br />to 55 jig/ml for the 500 mg/500 mg dose and from 56 to 88 jig/ml for the 1000<br />mg/1000 mg dose. The mean peak plasma levels of cilastatin following the 250<br />mg/250 mg, 500 mg/500 mg, and 1000 mg/1000 mg doses were 22, 42, and 72 jig/ml<br />respectively.<br />Distribution<br /><br />The binding of cilastatin to human serum proteins is approximately 40%.<br />Biotransformation and elimination<br />The plasma half-life of cilastatin is approximately one hour. Approximately 70-80% of<br />the dose of cilastatin was recovered unchanged in the urine as cilastatin within 10<br />hours of administration of imipenem/cilastatin. No further cilastatin appeared in the<br />urine thereafter. Approximately 10% was found as the N-acetyl metabolite, which has<br />inhibitory activity against dehydropeptidase comparable to that of cilastatin. Activity<br />of dehydropeptidase-I in the kidney returned to normal levels shortly after the<br />elimination of cilastatin from the blood stream.<br />Pharmacokinetics in special populations<br />Renal insufficiency<br />Following a single 250 mg/250 mg intravenous dose of imipenem/cilastatin, the area<br />under the curve (AUCs) for imipenem increased 1.1-fold, 1.9-fold, and 2.7-fold in<br />2<br />subjects with mild (Creatinine Clearance (CrCL) 50-80 ml/min/1.73 m ), moderate<br />2 2<br />(CrCL 30-&lt;50 ml/min/1.73 m ), and severe (CrCL &lt;30 ml/min/1.73 m) renal<br />impairment, respectively, compared to subjects with normal renal function (CrCL &gt;80<br />2<br />ml/min/1.73 m ), and AUCs for cilastatin increased 1.6-fold, 2.0-fold, and 6.2-fold in<br />subjects with mild, moderate, and severe renal impairment, respectively, compared to<br />subjects with normal renal function. Following a single 250 mg/250 mg intravenous<br />dose of imipenem/cilastatin given 24 hours after haemodialysis, AUCs for imipenem<br />and cilastatin were 3.7-fold and 16.4-fold higher, respectively, as compared to<br />subjects with normal renal function. Urinary recovery, renal clearance and plasma<br />clearance of imipenem and cilastatin decrease with decreasing renal function<br />following intravenous administration of imipenem/cilastatin. Dose adjustment is<br />necessary for patients with impaired renal function (see section 4.2).<br />Hepatic insufficiency<br />The pharmacokinetics of imipenem in patients with hepatic insufficiency have not<br />been established. Due to the limited extent of hepatic metabolism of imipenem, its<br />pharmacokinetics are not expected to be affected by hepatic impairment. Therefore,<br />no dose adjustment is recommended in patients with hepatic impairment (see section<br />4.2).<br />Paediatric population<br />The average clearance (CL) and volume of distribution (Vdss) for imipenem were<br />approximately 45% higher in paediatric patients (3 months to 14 years) as compared<br />to adults. The AUC for imipenem following administration of 15/15 mg/kg per body<br />weight of imipenem/cilastatin to paediatric patients was approximately 30% higher<br />than the exposure in adults receiving a 500 mg/500 mg dose. At the higher dose, the<br />exposure following administration of 25/25 mg/kg imipenem/cilastatin to children<br />was 9% higher as compared to the exposure in adults receiving a 1000 mg/1000 mg<br />dose.<br />Elderly<br />In healthy older volunteers (65 to 75 years of age with normal renal function for their<br />age), the pharmacokinetics of a single dose of imipenem/cilastatin 500 mg/500 mg<br /><br />administered intravenously over 20 minutes are consistent with those expected in<br />subjects with slight renal impairment for which no dosage alteration is considered<br />necessary. The mean plasma half-lives of imipenem and cilastatin were 91 &plusmn; 7.0<br />minutes and 69 &plusmn; 15 minutes, respectively. Multiple dosing has no effect on the<br />pharmacokinetics of either imipenem or cilastatin, and no accumulation of<br />imipenem/cilastatin was observed (see section 4.2).<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on repeated dose toxicity<br />and genotoxicity studies.<br />Animal studies showed that the toxicity produced by imipenem, as a single entity, was<br />limited to the kidney. Co-administration of cilastatin with imipenem in a 1:1 ratio<br />prevented the nephrotoxic effects of imipenem in rabbits and monkeys. Available<br />evidence suggests that cilastatin prevents the nephrotoxicity by preventing entry of<br />imipenem into the tubular cells.<br />A teratology study in pregnant cynomolgus monkeys given imipenem-cilastatin<br />sodium at doses of 40/40 mg/kg/day (bolus intravenous injection) resulted in maternal<br />toxicity including emesis, inappetence, body weight loss, diarrhoea, abortion, and<br />death in some cases. When doses of imipenem-cilastatin sodium (approximately<br />100/100 mg/kg/day or approximately 3 times the usual recommended daily human<br />intravenous dose) were administered to pregnant cynomolgus monkeys at an<br />intravenous infusion rate which mimics human clinical use, there was minimal<br />maternal intolerance (occasional emesis), no maternal deaths, no evidence of<br />teratogenicity, but an increase in embryonic loss relative to control groups (see<br />section 4.6).<br />Long term studies in animals have not been performed to evaluate carcinogenic<br />potential of imipenem-cilastatin.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sodium hydrogen carbonate<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product is chemically incompatible with lactate and should not be reconstituted<br />in diluents containing lactate. However, it can be administered into an I.V. system through<br />which a lactate solution is being infused.<br />This medicinal product must not be mixed with other medicinal products except those<br />mentioned in section 6.6.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.
Reconstituted solution: Reconstituted/diluted solutions should be used immediately.
The time interval between the beginning of reconstitution and the end of intravenous infusion
should not exceed two hours.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 25&ordm;C.<br />For storage conditions after reconstitution of the medicinal product, see section 6.3.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Imipenem/Cilastatin Kabi 500 mg/500 mg, powder for solution for infusion<br />Nature: uncolored glass vial Type III, 20 ml volume closed with bromobutyl rubber<br />stopper 20mm and covered with aluminum flip-off cap and uncolored glass bottle<br />Type II, 100 ml volume closed with bromobutyl rubber stopper 32mm and covered<br />with aluminum flip-off cap<br />Contents: Each pack contains: 10 x 20 ml vials and 10 x 100 ml bottles<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Each container is for single use only.<br />Reconstitution:<br />Contents of each container must be transferred to 50 mL (for 250mg strength) and 100 mL<br />(for 500mg strength) of an appropriate infusion solution (see section 6.2 and 6.3): 0.9%<br />sodium chloride. In exceptional circumstances where 0.9% sodium chloride cannot be used for<br />clinical reasons 5% glucose may be used instead.<br />A suggested procedure is to add approximately 10 ml of the appropriate infusion solution to<br />the container.<br />Shake well and transfer the resulting mixture to the infusion solution container.<br />CAUTION: THE MIXTURE IS NOT FOR DIRECT INFUSION.<br />Repeat with an additional 10 ml of infusion solution to ensure complete transfer of<br />container contents to the infusion solution. The resulting mixture should be agitated<br />until a clear solution is obtained.<br />16(17)<br />The concentration of the reconstituted solution following the above procedure is approximately<br />5 mg/ml for both imipenem and cilastatin.<br />Variations of colour, from colourless to yellow, do not affect the potency of the product.<br />Any unused medicinal product or waste material should be disposed of in accordance<br />with local requirements.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Fresenius Kabi Deutschland GmbH

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                May/2016
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>